Papadopoulos, Kyriakos P.
Ben-Ami, Eytan
Patnaik, Amita
Trone, Denise
Li, Jianke
Demetri, George D.
Funding for this research was provided by:
Daiichi Sankyo Company
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Paul’s Posse of the Pan Mass Challenge
Article History
Received: 8 February 2018
Accepted: 24 July 2018
First Online: 6 August 2018
Ethics approval and consent to participate
: This study was approved by the ethics committee of Southern Texas Accelerated Research Therapeutics (San Antonio, TX) and Dana-Farber Cancer Institute (Boston, MA), and patients provided written informed consent and indicated availability for periodic follow-up at the study site.
: Not applicable.
: Kyriakos P. Papadopoulos:Support to START from Ambit Biosciences for the conduct of clinical trials.Eytan Ben-Ami:The author(s) declare(s) that they have no competing interests.Amita Patnaik:Institutional funding from Daiichi Sankyo Pharma during the conduct of the study.Denise Trone:Employment:Daiichi Sankyo Pharma Development during the conduct of the study; Ambit Biosciences.Jianke Li:Employment:Daiichi Sankyo Inc. during the conduct of the study.George D. Demetri:Received grant/personal fees from Bayer, Daiichi Sankyo, Novartis, Pfizer; holds a patent at Dana-Farber licensed for imatinib use in GIST; holds minor equity as a member of the Board of Directors for Blueprint Medicines; is a member of the Scientific Advisory Board for Daiichi-Sankyo.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.